Salvage chemotherapy with cyclophosphamide, doxorubicin, and cisplatin [CAP] in advanced breast cancer
Medical Journal of the Islamic Republic of Iran. 1994; 8 (2): 75-80
en En
| IMEMR
| ID: emr-33678
Biblioteca responsable:
EMRO
Twenty-one patients with advanced breast cancer[7 premenopausal and 14 postmenopausal women] were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin [CAP]. The median age of the patients was 43 years [range 36-61]. This therapy was repeated every 3 weeks. Nine patients [group 1] received CAP as primary therapy for metastatic breast cancer, and twelve patients [group 2] received CAP as a second-line therapeutic agent. Of the 12 [57%] patients who responded, six [29%] had complete response [CR]. The median disease-free survival [DFS] was 8 months. The response rate was highest for metastases in the pleura [83%] and lymph nodes [81%], followed by skin [64%], liver and breast [55%]. The overall response rate was higher in previously untreated patients than in those previously treated [89% versus 33%, p<0.01]. Complete response rates of 44% and 17%, and median DFS of 10.5 and 3 months respectively, were observed in the two groups of patients. The therapy was well tolerated, myelosuppression being the dose limiting toxicity. The most frequent nonhematological toxicities were nausea, vomiting [100%], mucositis and stomatitis [38%], but these were rarely severe. Total alopecia occurred in only two patients. There were no toxic deaths or cardiotoxicity. Severe anemia occurred more frequently in group 2 patients. The present study suggests a role for CAP combination chemotherapy in the management of advanced breast cancer
Buscar en Google
Índice:
IMEMR
Asunto principal:
Neoplasias de la Mama
/
Doxorrubicina
/
Cisplatino
/
Ciclofosfamida
Límite:
Humans
Idioma:
En
Revista:
Med. J. Islamic Rep. Iran
Año:
1994